Apolipoprotein e genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for alzheimer disease

JAMA Psychiatry

Volumn 71, Issue 10, 2014, Pages 1183-1191

  Lautner, Ronald ^a   Palmqvist, Sebastian ^b,c   Mattsson, Niklas ^a,d   Andreasson, Ulf ^a   Wallin, Anders ^a   Pålsson, Erik ^a   Jakobsson, Joel ^a   Herukka, Sanna Kaisa ^e   Owenius, Rikard ^f   Olsson, Bob ^a   Hampel, Harald ^g   Rujescu, Dan ^h   Ewers, Michael ^d   Landén, Mikael ^a,i   Minthon, Lennart ^b,c   Blennow, Kaj ^a   Zetterberg, Henrik ^a,j   Hansson, Oskar ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f GE Healthcare Life Sciences   (Sweden)

^g SORBONNE UNIVERSITÉ   (France)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CARBON 11; FLUTEMETAMOL F 18; PHOSPHOPROTEIN; PITTSBURGH COMPOUND B; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSIS RELATED GROUP; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FINLAND; GENETIC ASSOCIATION; GENOTYPE; GERMANY; HETEROZYGOTE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRODROMAL SYMPTOM; PROTEIN CEREBROSPINAL FLUID LEVEL; PUNCTURE; SWEDEN; ALLELE; CEREBROSPINAL FLUID; GENETICS; MIDDLE AGED; REPRODUCIBILITY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; TAU PROTEINS; YOUNG ADULT;

EID: 84907805707     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1060     Document Type: Article

References (30)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
2. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312. doi:10.1101/cshperspect.a006312.
3. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3 (89):89ra57. doi:10.1126/scitranslmed.3002156.
4. Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19): 1807-1816.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 263-269.
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis ofmild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.
7. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131- 144.
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.
10. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937-945.
11. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid β-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE ε4 allele. Biol Psychiatry. 2004;56(9):670- 676.
12. Vemuri P, Wiste HJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67(3):308-316.
13. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology. 2004;62(11):2116-2118.
14. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med. 2011;49(3):375-383.
15. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci. 2012;47(1):1-14.
16. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A. The Goteborg MCI Study:mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry. 2005;76(11):1485- 1490.
17. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
18. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. 2010;21(4):1119-1128.
19. Andreasson U, Lautner R, Schott JM, et al. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4. Mol Psychiatry. 2014;19(2): 148-149.
20. Mattsson N, Rosen E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78(7):468-476.
21. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231-245.
22. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuro sci Lett. 2000;285(1):49- 52.
23. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680.
24. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336-345.
25. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative [18F] flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251-1259.
26. Lundqvist R, Lilja J, Thomas BA, et al. Implementation and validation of an adaptive template registrationmethod for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472-1478.
27. Mathis CA, Wang Y, Holt DP, Huang GF, DebnathML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13): 2740-2754.
28. Jagust WJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.
29. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69 (1):98-106.
30. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234.